WallStreetZenWallStreetZen

NASDAQ: INBS
Intelligent Bio Solutions Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their INBS stock forecasts and price targets.

Forecast return on equity

Is INBS forecast to generate an efficient return?

Company
-227.5%
Industry
21.05%
Market
143.92%
INBS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is INBS forecast to generate an efficient return on assets?

Company
-104.99%
Industry
11.9%
INBS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

INBS earnings per share forecast

What is INBS's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$5.28
Avg 2 year Forecast
-$4.14

INBS revenue forecast

What is INBS's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$6.3M+27.8%
Avg 2 year Forecast
$9.0M+83.86%
INBS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

INBS revenue growth forecast

How is INBS forecast to perform vs Medical Devices companies and vs the US market?

Company
35.59%
Industry
7.64%
Market
15.08%
INBS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
INBS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

INBS vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
INBS$2.51N/AN/A
CODX$1.21N/AN/A
PMI$3.21N/AN/AHold
NXL$0.33N/AN/A
AIDX$0.55$5.00+802.53%Strong Buy
View Top Medical Device Stocks

Intelligent Bio Solutions Stock Forecast FAQ

What is INBS's earnings growth forecast for 2027-2028?

(NASDAQ: INBS) Intelligent Bio Solutions's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 29.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 60.15%.

Intelligent Bio Solutions's earnings in 2026 is -$12,430,975.On average, 3 Wall Street analysts forecast INBS's earnings for 2027 to be -$15,995,940, with the lowest INBS earnings forecast at -$15,368,649, and the highest INBS earnings forecast at -$16,466,409.

In 2028, INBS is forecast to generate -$12,537,359 in earnings, with the lowest earnings forecast at -$12,045,698 and the highest earnings forecast at -$12,906,105.

If you're new to stock investing, here's how to buy Intelligent Bio Solutions stock.

What is INBS's revenue growth forecast for 2027-2028?

(NASDAQ: INBS) Intelligent Bio Solutions's forecast annual revenue growth rate of 35.59% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.64%, and it is also forecast to beat the US market's average forecast revenue growth rate of 15.08%.

Intelligent Bio Solutions's revenue in 2026 is $4,892,951.On average, 3 Wall Street analysts forecast INBS's revenue for 2027 to be $18,930,770, with the lowest INBS revenue forecast at $18,186,012, and the highest INBS revenue forecast at $19,487,824.

In 2028, INBS is forecast to generate $27,235,120 in revenue, with the lowest revenue forecast at $26,169,451 and the highest revenue forecast at $28,037,400.

What is INBS's forecast return on assets (ROA) for 2027-2028?

(NASDAQ: INBS) forecast ROA is -104.99%, which is lower than the forecast US Medical Devices industry average of 11.9%.

What is INBS's Earnings Per Share (EPS) forecast for 2027-2028?

(NASDAQ: INBS) Intelligent Bio Solutions's current Earnings Per Share (EPS) is -$8.44. On average, analysts forecast that INBS's EPS will be -$5.28 for 2027, with the lowest EPS forecast at -$5.08, and the highest EPS forecast at -$5.44. In 2028, INBS's EPS is forecast to hit -$4.14 (min: -$3.98, max: -$4.26).

What is INBS's forecast return on equity (ROE) for 2027-2028?

(NASDAQ: INBS) forecast ROE is -227.5%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.